Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 901 - 950 out of 3,730

Document Document Title
WO/2005/051932A1
Arylheterocycle derivatives which are represented by the formula (1): (1) wherein R1 represents C1-6 alkyl, etc.; R2 represents halogeno, etc.; m is an integer of 0 to 4; and T represents a group represented by the formula (2), (3), or (...  
WO/2005/040157A2
The present invention relates to a melanin concentrating hormone antagonist compound of formula I: or a pharmaceutically acceptable salt thereof, useful for the treamtment useful fog treating Type H diabetes and/or obesity.  
WO/2005/040127A1
The present invention relates to novel compounds accelerating the activity of Peroxisome proliferator-activated receptor gamma (PPAR&gammad ) and alpha (PPAR&agr ), processes of preparing the same, and pharmaceutical compositions contain...  
WO/2005/032465A2
The present invention encompasses compounds of Formula I: (I) as well as the pharmaceutically acceptable salts thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue ...  
WO/2005/032550A2
Novel PDF inhibitors and novel methods for their use are provided.  
WO/2005/030695A1
This invention provides a new method of obtaining a high density, reproducible and uniform coverage of a solid surface, compounds suitable for such a method and methods of preparing such compounds. This invention further relates to metho...  
WO/2005/030736A1
A description follows of 1,3-diones having general formula (I): together with their use as herbicides for the control of weeds in agricultural crops.  
WO/2005/030203A1
The present invention relates generally to substituted oxadiazolidinediones of the Formula (I); wherein R1 is hydrogen or -(CH2)nCOOH; n is an integer from 1 to 3; X is Formula (A), Formula (B), Formula (C) or Formula (D); as inhibitors ...  
WO/2005/030780A1
The present invention relates to a method (assay) for determining the activity of an enzyme selected from the group consisting of a sphingosine kinase and a phosphatase involved in the sphingolipid pathway by use of a labeled sphingosine.  
WO/2005/023787A1
The present invention relates to an improved and novel method for the manufacture of 2,1,3-benzoxadiazole-4-carboxaldehyde an intermediate for the preparation of 4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedi carboxylic aci...  
WO/2005/021490A2
The invention relates to N-sulfonyl-&agr -amino-acetic acid derivatives of the general formula (I): including the optical isomers thereof and mixtures of such isomers, wherein Ar1 and Ar2 independently of each other stand for an optional...  
WO/2005/020899A2
The present application describes modulators of MCP-1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.  
WO/2005/019147A2
There are described compounds of formula (I) wherein X1 and X2 are each independently of the other fluorine, chlorine or bromine; A1 and A2 are, for example, a bond or a C1-C6alkylene bridge; A3 is a C1-C6alkylene bridge; R1 and R2 are, ...  
WO/2005/019212A1
The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.  
WO/2005/019184A1
The present invention relates to novel compounds, methods, and formulations useful for the oral delivery of a GLP-1 compound or an MC4 agonist peptide.  
WO/2005/016870A1
Therapeutically active anthranilic acid derivatives of Formula (I) wherein R1, R2 and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds a...  
WO/2005/016344A1
This invention relates to a compound of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, wherein R1 to R5 are defined in the description, and to processes for the preparation thereof, intermediates used ...  
WO/2005/017126A2
The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding...  
WO/2005/013888A2
Compounds useful for treating cellular proliferative diseases and disorders by inhibiting the activity of KSP are disclosed.  
WO/2005/014563A1
The invention relates to compounds of formula (I) wherein the substituents are described in claim 1. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerativ...  
WO/2005/012241A2
Compounds and compositions for modulating the activity of p38 kinases are provided, including p38&agr , and p38β kinase. Methods for treating, preventing or ameliorating one or more symptoms of a p38 kinase mediated disease or disorder ...  
WO/2005/009941A1
The present invention relates to compounds of Formula I: I which are agonists of the M-1 muscarinic receptor.  
WO/2005/009998A1
This application relates to monomers of the general formula (I) for the preparation of PNA (peptide nucleic acid) oligomers and provides method for the synthesis of both predefined sequence PNA oligomers and random sequence PNA oligomers...  
WO/2005/005437A1
The present invention relates to an improved method for the manufacture of Isradipine, 4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedi carboxylic acid methyl 1-methylethyl ester. which, involves reacting 2,1,3-benzoxadiazole...  
WO/2005/001979A2
A fluorinated sulfonamide small molecule having the general structure (Formula I) wherein m, n and p are 0 to 3, with the proviso that m + n + p is equal to 1 to 4; A1 is an aromatic heterocyclic group, with the proviso that carbon atoms...  
WO/2005/000298A2
Provided are aminoaryl substituted 5-membered heterocycle-based p38 kinase, including p38alfa and p38beta. Pharmaceutical compositions containing the compounds are also provided. Method of use of the compounds and compositions are also p...  
WO/2004/108663A1
Fungicidal compounds of the general formula (1), wherein Ar is a group of the formula (A), (B1), (B2) or (C), or Ar is a 5- or 6-linked group of the formula (D1) or (D2); and R1, R2, R3, R4, R5, n, A1, A2, A3, A4, A5, Ka, Kb, L, M, V, W,...  
WO/2004/108661A1
The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is dir...  
WO/2004/103366A1
The present invention relates to substituted diphenyl heterocycle compounds according to structural formula (I) where the B ring is an aromatic ring that includes from one to four heteroatomes, and pharmaceutical compositions thereof tha...  
WO/2004/101537A1
Compounds formula (IA) or (IB); wherein W represents HO(C=0)-, HONH(C=0)- or H(C=O)N(OH)-; X represents -O- or -S-; and R1, R2, and R3 are as defined in the description and claims, are inhibitors of matrix metalloproteinases, in particul...  
WO2004083194B1
A blue light-emitting compound is disclosed which emits a blue light with high luminance for a long time when electrical energy is applied. A method for producing such a blue light-emitting compound and a light-emitting device utilizing ...  
WO/2004/099165A2
The present invention relates to substituted diphenyl heterocycle compounds according to formula (I), (II), (III) and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the us...  
WO/2004/096783A1
Compounds of formula (I), compositions, organic electronic devices, and methods for preparing organic electronic devices are described. The compounds of the invention contain at least two carbon-carbon triple bonds and a heteroaromatic r...  
WO/2004/096948A1
Compounds and compositions are provided that can be used as electron transport agents in organic electronic devices such as organic electroluminescent devices. The compounds are non-polymeric and have an aromatic core conjugated to end c...  
WO/2004/091502A2
Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease amelior...  
WO/2004/092116A1
Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical...  
WO/2004/089874A1
Compounds of formula (I) or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.  
WO/2004/087684A1
The present invention relates to novel benzo[1,2,5]oxadiazoles and benzo[1,2,5]thiadiazoles of formula (I) wherein X is O or S, R1 is 5-(2-fluoro-ethylamino)-thiazol-2-yl, 5-(2-18F-ethylamino)- thiazol-2-yl or a group of formula (a) wher...  
WO/2004/085411A1
This invention relates to novel heterocyclic compounds of formula (I) wherein R1- R4, X1 and X2 are as defined in the summary and pharmaceutically acceptable salts and solvates thereof, methods to inhibit or modulate Human Immunodeficien...  
WO/2004/080958A2
A novel process is provided for the preparation of substituted-5,6,7,8-tetrahydro[1,2,4]-triazolo[4,3-&agr ]pyrazines which are useful in the synthesis of dipeptidyl peptidase-IV inhibitors for the treatment of Type 2 diabetes. Also prov...  
WO/2004/080377A2
This invention relates to compounds of the general formula (I) useful as modulators of the KCNQ channel, to pharmaceutical compositions comprising these compounds, and to methods of treatment herewith.  
WO2004064972A9
Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the p...  
WO/2004/078734A1
This invention relates to novel tetrazole and oxadiazalone β-amino acids derivatives of the formula (I, II), wherein G is (III, IV) wherein R1 through R4 are defined as in the specification, pharmaceutical compositions containing them a...  
WO/2004/076420A1
A compound represented by the following formula (I): (I) [wherein X1 represents oxygen, etc.; X2 represents oxygen, etc.; R1 represents an alkylsulfonyl or another group on the ring A; R2 represents, e.g., C3-7 cyclic alkyl optionally su...  
WO/2004/073606A2
The present invention is directed to a compound of Formula (I):, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferat...  
WO/2004/072050A1
The present invention relates to compounds of formula (I) : wherein R1 is hydroxy, C1-4 alkoxy ,amino, C1-4 alkyl-amino, di C1-4 alkylamino , benzyloxy or C2-C7 alkanoyl, R2 is C1-4 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4 alkoxy, CF3, halog...  
WO/2004/069823A1
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell pr...  
WO/2004/067675A2
A blue electroluminescent material based on a binaphtyl compound of the general formula (I). Particular embodiments having the general formula have good solubilities in common organic solvents, resist crystallization and can be sublimed ...  
WO/2004/067506A2
Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina,...  
WO/2004/065360A2
The present invention relates to new enantiomerically pure piperazine derivatives of formula (I) wherein Y represents hydroxy or a leaving group and n is 1, 2, 3, 4 or 5, and to their use as synthesis intermediates, especially for the pr...  

Matches 901 - 950 out of 3,730